HTG Molecular Diagnostics (HTGM) Continues Upward Path; Boxer Capital Eyeing Opportunity in Esperion Therapeutics (ESPR)

Shares of HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) closed Thursday at $3.93, up $1.79 (or +83.64%) and continued an upward path – reaching a new 52-week high – in the extended session after the company delivered a robust revenue growth in its quarterly financial statement and said that initial testing results showed the feasibility of using its HTG EdgeSeq technology with the QIAGEN N.V.‘s (Nasdaq:QGEN) GeneReader next-generation sequencing (NGS) system.

For the fourth quarter 2016, HTG Molecular Diagnostics posted revenue of $1.46 million, a 19.9% increase year over year, and net loss – from operations – of ($5.2) million versus a net loss of ($5.3) million in the same period the prior year.

HTG Molecular Diagnostics, which develops and markets technology platforms that facilitate the routine use of complex molecular profiling, has 7.07M shares outstanding, At close on Thursday, the company had a market capitalization of $27.77M and HTGM stock one-year range was between $1.20 and $4.90 per share.


Hedge fund firm Boxer Capital, LLC disclosed after the closing-bell Thursday in a regulatory filing ( SC 13G ) with the Securities and Exchange Commission (SEC) a 6.8% passive stake (1,540,000 shares) in Esperion Therapeutics Inc. (Nasdaq:ESPR).

ESPR stock finished the regular session in positive territory by 3.56% (or +$1.39) at $40.40 with a total volume of 3.09M shares traded during the day.

Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), has 22.55M shares outstanding, market capitalization (intraday) of $879.91M and ESPR stock 52-week range is from $9.40 to $48.21 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at